Please upgrade your browser.
There is currently no established adjuvant therapy for renal cell carcinoma, although there have been a number of clinical trials exploring the effectiveness of various potential treatments.
Currently, tumor vaccines and chemotheraputic, biologic, and immunologic agents are being researched in the treatment of metastatic renal cell carcinoma, and some appear promising.
A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer
"Several therapies have been introduced in the past few years that have led to improvements in the way we treat advanced kidney cancer," says Joseph S. Camardo, M.D., Senior Vice President, Global Medical Affairs, Wyeth Pharmaceuticals. "In the INTORACT study, we hope to learn more about whether combining TORISEL with other agents in the first-line setting may further improve outcomes for patients with this devastating disease."
Radiofrequency ablation (RFA) showed similar effectiveness as surgical removal of renal tumours in curbing cancer recurrence rates for up to 5 years after treatment, according to a study published online in the journal Cancer.
Fox Chase Cancer Center researchers presented three abstracts at the 2010 annual meeting of the American Urological Association (AUA) that demonstrate progress in the use of the R.E.N.A.L. Nephrometry Scoring to characterize renal mass anatomy and allow standardization of surgical decision-making and comparison of outcomes in patients with kidney cancers.
Significant overall survival advantage for RCC patients treated with autologous tumor lysate vaccine
Advances in nephron-sparing surgery, laparoscopic approaches, and novel targeted therapies have dramatically improved the outcomes for patients with renal-cell carcinoma. Despite these advances, adjuvant treatment options following surgery are needed, and one approach that was shown to be successful in a previous multicenter phase III trial was an autologous tumor-based vaccine.
Bayer HealthCare and Kidney Cancer Association (KCA) honor medical reporting about renal cancer
A 74-year-old male is admitted to hospital for dyspnoea. Findings from chest x-ray, computed tomography, and colonoscopy are described; images provided.
. . . chemicals poured into sunscreen products are equally dubious. They include:TEA, DEA, MEA (tri-, di- and mono- ethaloamines). These chemicals can cause liver and kidney cancer.
Seattle Genetics has two proprietary ADCs in the clinic, one in late stage trials for Hodgkins Lymphoma and a second in early stage trials for non-Hodgkins Lymphoma and Renal Cell Carcinoma.
|Powered by NeonCRM|